{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T02:11:50Z","timestamp":1790907110183,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T00:00:00Z","timestamp":1732838400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T00:00:00Z","timestamp":1732838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23K19653"],"award-info":[{"award-number":["23K19653"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21KK0157"],"award-info":[{"award-number":["21KK0157"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21KK0157"],"award-info":[{"award-number":["21KK0157"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The accumulation of ascites is a major symptom of ovarian cancer. The volume of ascites is a pathophysiological indicator of the peritoneal environment, such as inflammation and fibrosis; however, the relationship between the volume of ascites and oncological outcomes remains unclear. We herein retrospectively examined the effects of the volume of ascites on the prognosis of epithelial ovarian cancer in a multi-institutional large cohort using the stratification of clinical characteristics and statistical adjustment methods.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Of 5,268 patients with ovarian tumors in the Tokai Ovarian Tumor Study Group between 1986 and 2020, we included 1,966 cases of epithelial ovarian cancer and examined the relationship between the volume of ascites at the initial surgery and the prognosis of patients. We performed a multivariate analysis and propensity score weighting for covariate adjustments to precisely estimate the prognostic impact of ascites accumulation. A subgroup analysis was also performed to examine differences in the prognostic implications of ascites accumulation among histotypes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A reservoir of 100 mL of ascites was confirmed as the cut-off value in our cohort. A Kaplan-Meyer analysis with propensity score adjustments indicated that the accumulation of more than 100 mL of ascites shortened overall survival. The multivariate analysis revealed that the increased accumulation of 100 mL of ascites was an independent prognostic factor for overall survival (HR 1.242; 95% CI 1.050\u20131.470; <jats:italic>P<\/jats:italic>\u2009=\u20090.012). The subgroup analysis showed the prognostic significance of ascites accumulation in mucinous and endometrioid histologies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The accumulation of even a low to intermediate volume of ascites (\u2265\u2009100 mL) was confirmed to be an independent poor prognostic factor in epithelial ovarian cancer. Furthermore, its prognostic impact differed among histotypes.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-024-13218-1","type":"journal-article","created":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T11:55:06Z","timestamp":1732881306000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Detailed analysis of the histology-specific impact of ascites volume on the outcome of epithelial ovarian cancer: a multi-institutional retrospective cohort study"],"prefix":"10.1186","volume":"24","author":[{"given":"Shohei","family":"Iyoshi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Yoshihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Kunishima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiri","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhisa","family":"Kitami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumasa","family":"Mogi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaname","family":"Uno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sho","family":"Tano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhisa","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Emoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeyuki","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Kajiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,29]]},"reference":[{"key":"13218_CR1","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3322\/caac.21456","volume":"68","author":"LA Torre","year":"2018","unstructured":"Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018;68:284\u201396.","journal-title":"CA Cancer J Clin"},{"key":"13218_CR2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41416-020-0875-x","volume":"123","author":"CE Ford","year":"2020","unstructured":"Ford CE, Werner B, Hacker NF, Warton K. The untapped potential of ascites in ovarian cancer research and treatment. Br J Cancer. 2020;123:9\u201316.","journal-title":"Br J Cancer"},{"key":"13218_CR3","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.2353\/ajpath.2010.100105","volume":"09","author":"E Lengyel","year":"2010","unstructured":"Lengyel E. Ovarian Cancer Development and Metastasis. Am J Pathol. 2010;09:177:1053\u201364.","journal-title":"Am J Pathol"},{"key":"13218_CR4","doi-asserted-by":"publisher","first-page":"2885","DOI":"10.1038\/s41388-018-0637-x","volume":"38","author":"T Motohara","year":"2019","unstructured":"Motohara T, Masuda K, Morotti M, Zheng Y, El-Sahhar S, Chong KY, et al. An evolving story of the metastatic voyage of ovarian cancer cells: cellular and molecular orchestration of the adipose-rich metastatic microenvironment. Oncogene 4\/. 2019;38:2885\u201398.","journal-title":"Oncogene 4\/"},{"key":"13218_CR5","doi-asserted-by":"crossref","unstructured":"Uno K, Iyoshi S, Yoshihara M, Kitami K, Mogi K, Fujimoto H et al. Metastatic voyage of Ovarian Cancer cells in Ascites with the assistance of various Cellular Components. Int J Mol Sci. 2022;23.","DOI":"10.3390\/ijms23084383"},{"key":"13218_CR6","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.tice.2016.11.004","volume":"49","author":"JOAM van Baal","year":"2017","unstructured":"van Baal JOAM, Van de Vijver KK, Nieuwland R, van Noorden CJF, van Driel WJ, Sturk A, et al. The histophysiology and pathophysiology of the peritoneum. Tissue Cell. 2017;49:95\u2013105.","journal-title":"Tissue Cell"},{"key":"13218_CR7","doi-asserted-by":"crossref","unstructured":"Aziz MAAE, Agarwal K, Dasari S, Mitra AAK. Productive cross-talk with the Microenvironment: a critical step in Ovarian Cancer Metastasis. Cancers. 2019;11.","DOI":"10.3390\/cancers11101608"},{"key":"13218_CR8","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/nrc1611","volume":"5","author":"H Naora","year":"2005","unstructured":"Naora H, Montell DJ. Ovarian cancer metastasis: integrating insights from disparate model organisms. Nat Rev Cancer. 2005;5:355\u201366.","journal-title":"Nat Rev Cancer"},{"key":"13218_CR9","doi-asserted-by":"publisher","first-page":"367103","DOI":"10.1155\/2014\/367103","volume":"2014","author":"T Feigenberg","year":"2014","unstructured":"Feigenberg T, Clarke B, Virtanen C, Plotkin A, Letarte M, Rosen B, et al. Molecular profiling and clinical outcome of high-grade serous ovarian cancer presenting with low- versus high-volume ascites. Biomed Res Int. 2014;2014:367103.","journal-title":"Biomed Res Int"},{"key":"13218_CR10","doi-asserted-by":"publisher","first-page":"5953","DOI":"10.21873\/anticanres.13800","volume":"39","author":"AN Coosemans","year":"2019","unstructured":"Coosemans AN, Baert T, D\u2019Heygere V, Wouters R, DE Laet L, VAN Hoylandt A, et al. Increased immunosuppression is related to increased amounts of Ascites and Inferior Prognosis in Ovarian Cancer. Anticancer Res. 2019;39:5953\u201362.","journal-title":"Anticancer Res"},{"key":"13218_CR11","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1136\/ijgc-2021-002978","volume":"31","author":"D Nasioudis","year":"2021","unstructured":"Nasioudis D, Byrne M, Ko EM, Haggerty AF, Cory L, Giuntoli RL, Ii, et al. Ascites volume at the time of primary debulking and overall survival of patients with advanced epithelial ovarian cancer. Int J Gynecol Cancer. 2021;31:1579\u201383.","journal-title":"Int J Gynecol Cancer"},{"key":"13218_CR12","doi-asserted-by":"publisher","first-page":"S91","DOI":"10.1016\/S0090-8258(21)00814-3","volume":"162","author":"D Nasioudis","year":"2021","unstructured":"Nasioudis D, Byrne M, Ko E, Haggerty A, Cory L, Giuntoli R, et al. Ascites volume at the time of primary debulking and overall survival of patients with advanced-stage epithelial ovarian cancer. Gynecol Oncol. 2021;162:S91.","journal-title":"Gynecol Oncol"},{"key":"13218_CR13","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.ygyno.2017.06.008","volume":"146","author":"JB Szender","year":"2017","unstructured":"Szender JB, Emmons T, Belliotti S, Dickson D, Khan A, Morrell K, et al. Impact of ascites volume on clinical outcomes in ovarian cancer: a cohort study. Gynecol Oncol. 2017;146:491\u20137.","journal-title":"Gynecol Oncol"},{"key":"13218_CR14","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1111\/jog.14682","volume":"47","author":"Q Quan","year":"2021","unstructured":"Quan Q, Zhou S, Liu Y, Yin W, Liao Q, Ren S, et al. Relationship between ascites volume and clinical outcomes in epithelial ovarian cancer. J Obstet Gynaecol Res. 2021;47:1527\u201335.","journal-title":"J Obstet Gynaecol Res"},{"key":"13218_CR15","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ygyno.2015.04.013","volume":"138","author":"JMT Janco","year":"2015","unstructured":"Janco JMT, Glaser G, Kim B, McGree ME, Weaver AL, Cliby WA, et al. Development of a prediction model for residual disease in newly diagnosed advanced ovarian cancer. Gynecol Oncol. 2015;138:70\u20137.","journal-title":"Gynecol Oncol"},{"key":"13218_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2019-000310","author":"I Lai","year":"2019","unstructured":"Lai I, Daniel MN, Rosen BP, May T, Massey C, Feigenberg T. Correlation of differential ascites volume with primary cytoreductive surgery outcome, lymph node involvement, and disease recurrence in advanced ovarian cancer. Int J Gynecol Cancer. 2019. https:\/\/doi.org\/10.1136\/ijgc-2019-000310.","journal-title":"Int J Gynecol Cancer"},{"issue":"10 Suppl","key":"13218_CR17","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.1002\/cncr.11345","volume":"97","author":"VW Chen","year":"2003","unstructured":"Chen VW, Ruiz B, Killeen JL, Cot\u00e9 TR, Wu XC, Correa CN. Pathology and classification of ovarian tumors. Cancer. 2003;97(10 Suppl):2631\u201342.","journal-title":"Cancer"},{"key":"13218_CR18","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s00404-014-3364-8","volume":"290","author":"F Zeppernick","year":"2014","unstructured":"Zeppernick F, Meinhold-Heerlein I. The new FIGO staging system for ovarian, fallopian tube, and primary peritoneal cancer. Arch Gynecol Obstet. 2014;290:839\u201342.","journal-title":"Arch Gynecol Obstet"},{"key":"13218_CR19","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1093\/jjco\/hyy206","volume":"49","author":"H Tokunaga","year":"2019","unstructured":"Tokunaga H, Shimada M, Ishikawa M, Yaegashi N. TNM classification of gynaecological malignant tumours, eighth edition: changes between the seventh and eighth editions. Jpn J Clin Oncol. 2019;49:311\u201320.","journal-title":"Jpn J Clin Oncol"},{"key":"13218_CR20","unstructured":"National Comprehensive Cancer Network, NCCN Clinical Practice Guideline in Oncology; Ovarian Cancer\/Fallopian Tube Cancer\/Primary Peritoneal Cancer, version 3. 2024. Available at: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1453. Retrieved 25 November 2024."},{"key":"13218_CR21","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s10147-016-0985-x","volume":"21","author":"S Komiyama","year":"2016","unstructured":"Komiyama S, Katabuchi H, Mikami M, Nagase S, Okamoto A, Ito K, et al. Japan Society of Gynecologic Oncology guidelines 2015 for the treatment of ovarian cancer including primary peritoneal cancer and fallopian tube cancer. Int J Clin Oncol. 2016;21:435\u201346.","journal-title":"Int J Clin Oncol"},{"key":"13218_CR22","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1093\/annonc\/mdn059","volume":"19","author":"S Suzuki","year":"2008","unstructured":"Suzuki S, Kajiyama H, Shibata K, Ino K, Nawa A, Sakakibara K, et al. Is there any association between retroperitoneal lymphadenectomy and survival benefit in ovarian clear cell carcinoma patients? Ann Oncol. 2008;19:1284\u20137.","journal-title":"Ann Oncol"},{"key":"13218_CR23","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1097\/IGC.0b013e3182070f17","volume":"21","author":"GJS Rustin","year":"2011","unstructured":"Rustin GJS, Vergote I, Eisenhauer E, Pujade-Lauraine E, Quinn M, Thigpen T, et al. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer. 2011;21:419\u201323.","journal-title":"Int J Gynecol Cancer"},{"key":"13218_CR24","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1080\/01621459.1984.10478078","volume":"79","author":"PR Rosenbaum","year":"1984","unstructured":"Rosenbaum PR, Rubin DB. Reducing Bias in Observational studies using subclassification on the Propensity score. J Am Stat Assoc. 1984;79:516\u201324.","journal-title":"J Am Stat Assoc"},{"key":"13218_CR25","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1186\/s13054-015-1086-3","volume":"19","author":"M Yoshihara","year":"2015","unstructured":"Yoshihara M, Uno K, Tano S, Mayama M, Ukai M, Kondo S, et al. The efficacy of recombinant human soluble thrombomodulin for obstetric disseminated intravascular coagulation: a retrospective study. Crit Care. 2015;19:369.","journal-title":"Crit Care"},{"key":"13218_CR26","doi-asserted-by":"crossref","unstructured":"Manning-Geist BL, Hicks-Courant K, Gockley AA, Clark RM, Del Carmen MG, Growdon WB et al. A novel classification of residual disease after interval debulking surgery for advanced-stage ovarian cancer to better distinguish oncologic outcome. Am J Obstet Gynecol. 2019;221:326.e1-326.e7.","DOI":"10.1016\/j.ajog.2019.05.006"},{"key":"13218_CR27","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12967-020-02295-y","volume":"18","author":"Y Dabi","year":"2020","unstructured":"Dabi Y, Huchon C, Ouldamer L, Bendifallah S, Collinet P, Bricou A, et al. Patients with stage IV epithelial ovarian cancer: understanding the determinants of survival. J Transl Med. 2020;18:134.","journal-title":"J Transl Med"},{"key":"13218_CR28","doi-asserted-by":"publisher","first-page":"eaax5611","DOI":"10.1126\/sciadv.aax5611","volume":"01","author":"Y Li","year":"2020","unstructured":"Li Y, Mao AS, Seo BR, Zhao X, Gupta SK, Chen M, et al. Compression-induced dedifferentiation of adipocytes promotes tumor progression. Sci Adv. 2020;01:6:eaax5611.","journal-title":"Sci Adv"},{"key":"13218_CR29","doi-asserted-by":"publisher","unstructured":"Shohei, Iyoshi Masato, Yoshihara Kae, Nakamura Mai, Sugiyama Yoshihiro, Koya Kazuhisa, Kitami Kaname, Uno Kazumasa, Mogi Sho, Tano Hiroyuki, Tomita Keiji, Kajiwara Masayasu, Taki Shigehiro, Yamaguchi Akihiro, Nawa Hiroaki, Kajiyama (2021) Pro\u2010tumoral behavior of omental adipocyte\u2010derived fibroblasts in tumor microenvironment at the metastatic site of ovarian cancer Abstract International Journal of Cancer 149(11) 1961-1972. https:\/\/doi.org\/10.1002\/ijc.v149.11.","DOI":"10.1002\/ijc.v149.11"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-13218-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-024-13218-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-13218-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T12:02:59Z","timestamp":1732881779000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-024-13218-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,29]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["13218"],"URL":"https:\/\/doi.org\/10.1186\/s12885-024-13218-1","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,29]]},"assertion":[{"value":"22 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Nagoya University (No. 2006\u2009\u2212\u20090357) in accordance with the principles of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1479"}}